The nation of Zimbabwe has turned down a major US health deal worth 367 million US dollars (£272m) spanning five years over Washington's insistence on confidential biological samples.
This rejection became public following a internal memorandum dated December was disclosed, which showed Head of State Emmerson Mnangagwa felt the agreement was "skewed".
An official representative later stated that the United States was requesting genetic material for scientific study and commercial gain while refused to guarantee the resulting advantages from any future treatments.
"We are forced to start the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had provided over $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has appealed for more negotiations to find a deal suitable to both sides so the country's vital HIV treatment initiative can be sustained.
Broader Context
This development follows a similar situation in Kenya, where a court blocked a related health funding agreement following concerns were filed about the safety of Kenyans' medical information.
After resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had managed assistance for the US government, but Trump stated its expenditure was "wasteful" and his government was pursuing direct bilateral deals to enhance transparency and accountability.
Based on reports, 16 nations in Africa have so far agreed to similar health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration would have delivered extraordinary advantages for the people of Zimbabwe, especially the 1.2 million presently receiving antiretroviral therapy through American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, without any corresponding guarantee of benefiting from any medical innovations – like new medicines or tests – that might be developed from that shared data," he stated.
"In essence, our country would provide the basic resources for medical research with no certainty that the final treatments would be available to our people if a future disease outbreak arise."
National Interest and Global Health
He also pointed out that the American exit from the global health body and its push of bilateral deals were undermining systems previously set up through the global organization.
Mangwana cited its Pandemic Benefit-Sharing framework created to deal with future pandemics.
"This mechanism is intended to guarantee that when a nation contributes its data, the benefits – such as medicines and cures – are distributed fairly, not monopolised solely by those with the funds to create them."
These objections regarding the US deal "are not meant as anti-American sentiment," he added.
"We encourage further discussions with our US partners on how future co-operation might be structured in a manner that honours the sovereignty and interests of both nations."
Medical Community Response
A leading public health body said it understood the government's concerns, but recommended that negotiations must proceed considering much of the country's Aids initiatives relied on international support.
"If specific concerns arise, such as those relating to information security or agreement terms, these can frequently be addressed via detailed discussion and mutually agreed protections," the group commented.
This impasse highlights the complex challenges between accepting much-needed international aid and safeguarding a country's data in an increasingly interconnected world.